Klaus Reither

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 385 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 249 citations

Medicine, Pharmacology, Pharmacotherapy +11

Preferential infection and depletion of <i>Mycobacterium tuberculosis</i> –specific CD4 T cells after HIV-1 infection

Christof Geldmacher, Njabulo Ngwenyama, Alexandra Schuetz et al. · The Journal of Experimental Medicine · 2010 · 235 citations · Full text

Life Sciences, Immunology, Microbiology +17

Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study

Andrea Rachow, Alimuddin Zumla, Norbert Heinrich et al. · PLoS ONE · 2011 · 164 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study

Andrea Rachow, Petra Clowes, Elmar Saathoff et al. · Clinical Infectious Diseases · 2012 · 150 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17